Effects of omega-3 fatty acids in inflammatory bowel diseases: a literature review
DOI:
https://doi.org/10.15448/1983-652X.2014.2.13377Keywords:
inflammatory bowel diseases, Crohns disease, proctocolitis, omega-3 fatty acidsAbstract
Introduction: Polyunsaturated omega-3 (ω3) fatty acids have many beneficial effects on human health. Among these, it has anti-inflammatory effect, decreasing the synthesis of derivatives of the arachidonic acid (AA). Therefore, it is believed that the supplementation of fish oil containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) could reduce the effects of inflammatory processes by decreasing the synthesis of eicosanoid precursors of inflammation, as well as the use of anti-inflammatory drugs. Objective: The purpose of this paper was to describe the effects of therapy based on nutritional supplementation of omega-3 in patients with inflammatory bowel disease (IBD) in a literature review. Materials and Methods: This is a review of the literature made in journals indexed in Medline, Lilacs, Scielo and Pubmed databases, in Portuguese, English and Spanish, and covered the articles published between 1989 and 2014. Results: Of 179 analyzed articles on inflammatory bowel disease, after inclusion and exclusion criteria were applied, 18 articles were selected from randomized clinical trials, observational, epidemiological, cohort and case-control in humans. Conclusions: The dose of ω3 used in these experiments was on average 4,5g/day. EPA and DHA are incorporated into the tissue of the intestinal mucosa of patients with IBD that complement the diet with fish oil resulting in anti-inflammatory effect with improvement in clinical outcomes, in the intestinal mucosa histology, in the results of sigmoidoscopy, as well as a lower relapse rate and decreased use of corticosteroids.References
Simopoulos AP. Omega-6/omega-3 essential fatty acid ratio and chronic diseases. Food Rev Int. 2004; 20(1):77-90.
Simopoulos AP. n-3 fatty acids in the prevention-management of cardiovascular disease. Canadian Journal of Physiology and Pharmacology. 1997;75: 234-239.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of the American College of Nutrition. 2002; 21(6):495-505.
Bistrian BR. Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads lecture. JPEN. 2003; 27(3):168.
Douglas CR. Patofisiologia geral: mecanismo da doença. 2ª ed. São Paulo: Robe; 2000. p. 514-31.
Martin CA, Almeida VV, Ruiz MR, Visentainer JEL, Matshushita M, Visentainer JV. Ácidos graxos poliinsaturados ômega-3 e ômega-6: importância e ocorrência em alimentos. Rev Nutr. 2006; 19(6):761-70.
Mahan LK, Escott-Stump S. Lipídeos. In: Krause:
alimentos, nutrição & dietoterapia. 9ª ed. São Paulo: Roca; 1998. p. 51-3.
Thompson WA, Lowry SF. Effect of nutrition on inflammatory mediators. In: Zaloga GP. Nutriti on in critical care. St Louis: Mosby; 1994. p. 505-23.
Fürst P. The striking diet of the island of Crete: lipid nutrition from the palaeolithic to the affluent modern society. Clin Nutr. 2002; 21(S2):9-14.
James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000; 71(S):343-8.
Kelley DS. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition. 2001; 17:669-73.
Robert O. Practical applications of fish oil (w-3 fatty acids) in primary care. J Am Board Pract. 2005; 18:28-36.
Frias ACD. Utilização de ácidos graxos da família ômega-3 na prevenção de doenças cardiovasculares: revisão de literatura. Bauru (SP): Ed. Universidade do Sagrado Coração; 1995.
Institute of Medicine. Dietary Reference Intakes (DRIs) for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Part 1. Washington (DC): National Academy Press; 2002.
Agency for Healthcare Research and Quality. Effects of omega-3 fatty acids on organ transplantation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005. p.115.
Scientific Review Committee. Nutrition recommendations. Ottawa: Canadian Government Publishing Centre, Supply and Services Canada; 1990.
Simopoulos AP, Leaf A, Salem N. Essentiality and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metabol. 1999; 43(3):127-30.
Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr. 2002; 75(2):191-212.
Chardigny JM, Bretillon L, Sébédio JL. New insights in health effects of trans alpha-linolenic acid isomers in humans. Eur J Lipid Sci Technol. 2001; 103(7):478-82.
Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000; 71(1 Suppl):179S-88.
Nordic Council of Ministers. Nordic nutrition recommendations. Scand J Nutr. 1996; 40(4):161-5.
World Health Organization. Joint Consultation: fats and oils in human nutrition. Nutr Rev. 1995; 53(7):202-5.
Uchiyama K, Nakamura M, Odahara S, Koido S, Katahira K, Shiraishi H, Ohkusa T, Fujise K, Tajiri H. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease Inflamm Bowel Dis. 2010; 16(10):1696-707.
Silva AFM, Schieferdecker EM, Amarante HMBS. Ingestão alimentar em pacientes com doença inflamatória intestinal. Arq Bras Cir Dig. 2011;24(3):204-9.
Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992; 87:432–7.
Stenson WF, Cort D, Rodgers J, Burakoff R, DeSchyver-Kecskemeti K, Gramlich TL, Beeken W. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992; 116:609-14.
Almallah YZ , Richardson S, O'Hanrahan T, Mowat NAG, Brunt PW , Sinclair TS, Ewen S, Heys SD, Eremin O. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998;93:804-9.
Varghese TJ, Coomansingh D. Clinical response of ulcerative colitis with dietary omega-3 fatty acids: a double-blind randomized study. Br J Surg. 2000;87:73.
Almallah YZ, Ewen SW, El-Tahir A, Mowat NAG, Brunt, PW, Sinclair TS, Heys SD, Eremin O. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): The mucosal effect in situ. J Clin Immunol. 2000; 20:68-76.
Greenfield SM, Green AT, Teare JP, Jenkins, AP, Punchard NA, Ainley CC, Thompson RPH. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther. 1993; 7:159-66.
Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, Malkinson C, Shaheen MZ, Willars JE. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut. 1992; 33:922-8.
Mantzaris GJ, Archavlis E, Zografos C, Petraki K, Spiliades C, Triantafyllou G. A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis. J Gastroenterol. 1996; 9:138-41.
Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther. 2002; 16:1131-5.
Loeschke K, Ueberschaer B, Pietsch A, Gruber E, Ewe K, Wiebecke B, Heldwein W, Lorenz R. N-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci. 1996;41:2087-94
Nielsen AA, Jorgensen LG, Nielsen JN, Eivindson M, Grønbaek H, Vind I, Hougaard DM, Skogstrand K, Jensen S, Munkholm P, Brandslund I, Hey H. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn’s disease compared with omega-6 fatty acids. Aliment Pharmacol Ther 2005; 22(11-12):1121-8.
Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: A double-blind randomized controlled trial with two years follow-up Inflamm Bowel Dis. 2012; 18(2):246-53.
Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation
on relapses in Crohn’s disease. N Engl J Med. 1996; 334:1557-60.
Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, Scheurlen C, Koop I, Pudel V, Carr L. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. A randomized controlled multicenter trial. Study Group Members (German Crohn’s Disease Study Group). Scand J Gastroenterol.1996; 31:778-85.
Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D’Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JWD, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: The EPIC Randomized Controlled Trials. JAMA. 2008; 299:1690-7.
Trebble TM, Arden NK, Wootton SA, Calder PC, Mulee MA, Fine DR, Stroud MA. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn’s disease. AmJ Clin Nutr. 2004; 80:1137-44.
Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: a randomized, placebo-controlled, double-blind cross-over trial. J InternMed Suppl. 1989;731:225-32.
Furst P, Kuhn KS. Essentiaity of recommended dietary intakes for omega 6 and omega 3 fatty acids. Ann Nutr Metab, 2000; 43:127-30.
Gomes TKC, Oliveira SL. O papel dos ácidos graxos essenciais no perfil de eicosanoides e sua repercussão na resposta imune. Nutrire 2010; 35(1):167-86.
Tabela brasileira de composição de alimentos / NEPA –UNICAMP. 4. ed. rev. e ampl. Campinas: NEPA – UNICAMP; 2011. 161 p.
Downloads
Published
Issue
Section
License
COPYRIGHT
The submission of originals to Ciência & Saúde implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Ciência & Saúde as the site of original publication.
CREATIVE COMMONS LICENSE
As this journal is open access, the articles are allowed free use in scientific and educational applications, with citation of the source.
According to the type of Creative Commons License (CC-BY 4.0) adopted by Ciência & Saúde , the user must respect the requirements below.
You are free to:
Share — copy and redistribute the material in any medium or format.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
However, only under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests Ciência & Saúde endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
For more details on the Creative Commons license, please follow the link in the footer of this website.
